Skip to main content

Pharmacokinetics, Pharmacodynamics and much more.....

BayBiotech.NET
This blog is focused on discussing some of the terminology you may come across while dealing with Quality Control/Assurance or regulatory compliance in a Pharmaceutical/ Life sciences Industry environment.
We may not dedicate many blogs on this, but briefly going over them, will provide us the acquaintance with theses terms and may help understand them better whenever they are referenced in other documents/ blogs. These are as follows:

Pharmaceutics: discipline of pharmacology that involves evaluation, design and preparation of suitable dosage forms of chemical entities and delivery systems. This discipline is targeted towards optimizing drug action as well as minimizing adverse effects. Pharmaceutics involves studies from interdependent areas such as physical chemistry, biochemistry, analytical chemistry, mathematics, chemical engineering, molecular and cellular biology, pharmacology, anatomy and physiology.

Pharmacokinetics: is the study of the time course of drug in different fluids, tissues, and excreta of the body (effect of body on the drug).

ADME (T): is a term used for absorption, distribution, metabolism, excretion and toxicology studies.

Pharmacodynamics: study of the physiological effects of ingested drugs within or on the body. (effect of drug on the body).

Pharmacogenomics: study of how an individual's genetic constitution affects body's response to drugs.

Pharmaceutical Formulation: process in which different substances, including the active drug, are combined to produce a final medicinal product.

Biologics: studying a wide range of medicinal products of biological origin. Examples are vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. In most of the jurisdictions worldwide, biologics are regulated in a different manner than are drugs and medical devices.

Bioequivalence: United States Food and Drug Administration (FDA) has defined bioequivalence as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. These studies are mainly conducted to compare two products such as a commercially-available Brand product and a potential to-be-marketed Generic product.

Bioavailability: is the fraction of the administered dose that reaches the systemic circulation.

Potency and Efficacy: Potency refers to the amount of drug (usually expressed in milligrams) needed to produce an effect. Efficacy refers to the potential maximum therapeutic response that a drug can produce.

Dose Response: measured as LD50 or statistically-derived dose that is lethal to 50% of a modeled population.

Pharmacovigilance: is the science of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of medications.

References:

1. Gibaldi, M. and Perrier, D. 1975 Pharmacokinetics, Marcel Dekker, page v.
2. J. Lazarou, B. H. Pomeranz, and P. N. Corey. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. Apr 15, 1998. 279(15):1200-5.
3. J. Hodgson, and A. Marshall. Pharmacogenomics: will the regulators approve? Nature Biotechnolgy. 16: 243-246. 1998.
4. S. Pistoi. Facing your genetic destiny, part II. Scientific American. February 25, 2002.
5. Genomics.energy.gov
6. Wikipedia (en.wikipedia.org)
7. accelrys.com
8. http://www.fas.org/ota/reports/7401.pdf
9. http://aquaticpath.umd.edu/appliedtox/dose-response.pdf
10. www.fda.gov

Comments

Post a Comment

Popular posts from this blog

FDA Launches Medical Device and Radiation-Emitting Product Transparency Web Site

BayBiotech.NET On April 19th, 2010 FDA launched he Center for Devices and Radiological Health (CDRH) Transparency Web site in support of the agency’s Transparency Initiative. The Web site makes available new information about CDRH’s decision-making processes and displays this information in a more user-friendly format. The site includes new information such as basic information about medical devices and how FDA regulates those products, information about medical devices before and after the products are on the market, in a searchable database, information about the clinical studies and trials conducted to demonstrate the safety and effectiveness of certain medical devices, memos from FDA employees explaining the reasons for the agency's decisions about medical device manufacturer requests to make a significant change in components, materials, design, specification, software, color additive, and labeling of a medical device as well as a step-by-step guide for manufacturers of
1 comment
Read more

eCTD Submission Specifications

BayBiotech.NET The electronic Common Technical Document (eCTD) is an interface for the pharmaceutical industry to agency transfer of regulatory information. eCTD technical document format development was done by International Conference on Harmonization (ICH) Multidisciplinary Group 2 Expert Working Group (ICH M2 EWG). Details on the specification for the ICH eCTD can be found in the guidance document M2 eCTD: Electronic Common Technical Document Specification. Currently, eCTD is the preferred format for electronic submissions by U.S. Food and Drug Administration. Although originally the CTD and the eCTD were designed for marketing applications, they could apply equally to other submission types, including INDs, master files, advertising material, and promotional labeling. In June 2008, FDA has issued guidelines for organizing the electronic regulatory document filing using the eCTD tools. This guidance discusses issues related to the electronic submission of applications for hum
Post a Comment
Read more

Harmonization by Doing (HBD): Japan & U.S. Collaboration

BayBiotech.NET HBD is an international cooperative effort by Japan and US for regulatory convergence for Medical Devices. The efforts are focused on to develop global clinical trials and address regulatory barriers for timely device approvals. To address the needs for additional evaluation, the HBD initiative is a pilot project launched jointly by FDA and MHLW-PMDA for the premarket review of device cardiovascular technology. Instead of taking a theoretical approach to harmonization, HBD is focused on Proof of concept by utilizing parallel development, application submissions and review of actual medical device projects. HBD Study intends to collect and analyze regulatory submission data from multiple applications in the U.S. and Japan. The purpose of the study is to further understand differences that may exist with format and content, to define best practices and to improve globally harmonized processes. To read more about the HBD program, follow the link: http://www.fda.gov/M
Post a Comment
Read more